VARENICLINE TARTRATE (varenicline) by Medica Corp is α4β2 neuronal nicotinic acetylcholine receptors. First approved in 2023.
Drug data last refreshed 18h ago
α4β2 neuronal nicotinic acetylcholine receptors. The efficacy of varenicline tablets in smoking cessation is believed to be the result of varenicline’s activity at α4β2 sub-type of the nicotinic receptor where its binding produces agonist activity, while simultaneously preventing nicotine binding…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation
Effectiveness of Combination Varenicline and Oral Nicotine Replacement Therapy (COMBO)
Deep rTMS and Varenicline for Smoking Cessation
A Trial of Directly Observed and Long-term Varenicline
Combining rTMS With Varenicline to Prevent Smoking Lapse in Schizophrenia
Worked on VARENICLINE TARTRATE at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.